Search Videos and More

Showing 1 - 12 of 422 results

Previous| 1 | 2 | 3 ...36 |Next


Dana-Farber Research News 11.01.2024 News

Dana-Farber Research News 11.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 1 through October 15.
Dana-Farber Research News 10.15.2024 News

Dana-Farber Research News 10.15.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 through September 30.
Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives News

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.
Study Finds Unexpected Role for Odd-Man-Out Member of CDK Protein Family News

Study Finds Unexpected Role for Odd-Man-Out Member of CDK Protein Family

In the family of cyclin-dependent kinase (CDK) proteins, CDK5 always seemed to be a misfit. Despite being structurally similar to other CDKs, and despite the “cyclin” in its name, it did not participate in the family business of ushering cells through the cycle of growth and division. 
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row News

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.
Dana-Farber Research News 10.01.2024 News

Dana-Farber Research News 10.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 through September 15.
Dana-Farber Cancer Institute Raises More Than $2 Billion in Record-Breaking Fundraising Campaign to Defy Cancer News

Dana-Farber Cancer Institute Raises More Than $2 Billion in Record-Breaking Fundraising Campaign to Defy Cancer

Dana-Farber Cancer Institute today announced the completion of one of the largest fundraising campaigns focused entirely on cancer, raising a record $2.5 billion. 
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care News

Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care

In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium.
Prostate Cancer Vaccines: What’s the Latest? News

Prostate Cancer Vaccines: What’s the Latest?

Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.? 
Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain News

Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain

When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders. 
Dana-Farber Research News 9.15.2024 News

Dana-Farber Research News 9.15.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 through August 31.
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer News

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.

Showing 1 - 12 of 422 results

Previous| 1 | 2 | 3 ...36 |Next